2023
Novel Targeted Therapies for Renal Cell Carcinoma Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition
Saliby R, Saad E, Labaki C, Xu W, Braun D, Viswanathan S, Bakouny Z. Novel Targeted Therapies for Renal Cell Carcinoma Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition. Hematology/Oncology Clinics Of North America 2023, 37: 1015-1026. PMID: 37385938, DOI: 10.1016/j.hoc.2023.05.022.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaTreatment of RCCTargeted therapyNovel Targeted TherapiesVHL/HIF pathwayVascular endothelial growth factorEndothelial growth factorCell carcinomaMetabolic targetingMTOR inhibitionMTOR pathwayGrowth factorTherapyPromising novelHIF pathwayTreatmentOxygen homeostasisEpigenomic reprogrammingRemarkable advancesPathwayCarcinoma
2017
Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies
Braun D, Wu C. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. The Cancer Journal 2017, 23: 115-124. PMID: 28410299, PMCID: PMC5856170, DOI: 10.1097/ppo.0000000000000257.Peer-Reviewed Original ResearchConceptsHematologic malignanciesAntigen discoveryImmune-based therapiesStem cell transplantationNovel tumor antigensAdoptive cell therapyInvestigational immunotherapiesImmune therapyCancer vaccinesCell transplantationTreatment modalitiesTumor antigensAntitumor effectsTherapeutic targetingMalignancyMalignant cellsImmunotherapyCell therapyTherapyActive investigationTreatmentFurther investigationTransplantationVaccineAntigen